366 related articles for article (PubMed ID: 29846705)
21. Risk of Venous Thromboembolism in Grade II-IV Gliomas as a Function of Molecular Subtype.
Diaz M; Jo J; Smolkin M; Ratcliffe SJ; Schiff D
Neurology; 2021 Feb; 96(7):e1063-e1069. PubMed ID: 33361259
[TBL] [Abstract][Full Text] [Related]
22. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K
Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105
[TBL] [Abstract][Full Text] [Related]
23. A three-component multi-b-value diffusion-weighted imaging might be a useful biomarker for detecting microstructural features in gliomas with differences in malignancy and IDH-1 mutation status.
Cao M; Wang X; Liu F; Xue K; Dai Y; Zhou Y
Eur Radiol; 2023 Apr; 33(4):2871-2880. PubMed ID: 36346441
[TBL] [Abstract][Full Text] [Related]
24. TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.
Zhang ZY; Chan AK; Ding XJ; Qin ZY; Hong CS; Chen LC; Zhang X; Zhao FP; Wang Y; Wang Y; Zhou LF; Zhuang Z; Ng HK; Yan H; Yao Y; Mao Y
Oncotarget; 2015 Sep; 6(28):24871-83. PubMed ID: 26314843
[TBL] [Abstract][Full Text] [Related]
25. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis.
Sun H; Yin L; Li S; Han S; Song G; Liu N; Yan C
J Neurooncol; 2013 Jun; 113(2):277-84. PubMed ID: 23504258
[TBL] [Abstract][Full Text] [Related]
27. RUNX1 and REXO2 are associated with the heterogeneity and prognosis of IDH wild type lower grade glioma.
Wang H; Wang X; Xu L; Zhang J; Cao H
Sci Rep; 2021 Jun; 11(1):11836. PubMed ID: 34088969
[TBL] [Abstract][Full Text] [Related]
28. Inherited variant on chromosome 11q23 increases susceptibility to IDH-mutated but not IDH-normal gliomas regardless of grade or histology.
Rice T; Zheng S; Decker PA; Walsh KM; Bracci P; Xiao Y; McCoy LS; Smirnov I; Patoka JS; Hansen HM; Hsuang G; Wiemels JL; Tihan T; Pico AR; Prados MD; Chang SM; Berger MS; Caron A; Fink S; Kollmeyer T; Rynearson A; Voss J; Kosel ML; Fridley BL; Lachance DH; Eckel-Passow JE; Sicotte H; O'Neill BP; Giannini C; Wiencke JK; Jenkins RB; Wrensch MR
Neuro Oncol; 2013 May; 15(5):535-41. PubMed ID: 23361564
[TBL] [Abstract][Full Text] [Related]
29. TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline.
Sun ZL; Chan AK; Chen LC; Tang C; Zhang ZY; Ding XJ; Wang Y; Sun CR; Ng HK; Yao Y; Zhou LF
Int J Clin Exp Pathol; 2015; 8(9):11485-94. PubMed ID: 26617880
[TBL] [Abstract][Full Text] [Related]
30. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
[TBL] [Abstract][Full Text] [Related]
31. Suppression of antitumor immune signatures and upregulation of VEGFA as IDH-mutant gliomas progress to higher grade.
Grewal EP; Richardson LGK; Sun J; Ramapriyan R; Martinez-Lage M; Miller JJ; Cahill DP; Choi BD; Curry WT
Neurosurg Focus; 2024 Feb; 56(2):E2. PubMed ID: 38301244
[TBL] [Abstract][Full Text] [Related]
32. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
33. IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients.
Metellus P; Colin C; Taieb D; Guedj E; Nanni-Metellus I; de Paula AM; Colavolpe C; Fuentes S; Dufour H; Barrie M; Chinot O; Ouafik L; Figarella-Branger D
J Neurooncol; 2011 Dec; 105(3):591-600. PubMed ID: 21643985
[TBL] [Abstract][Full Text] [Related]
34. IDH mutations but not TERTp mutations are associated with seizures in lower-grade gliomas.
Duan WC; Wang L; Li K; Wang WW; Zhan YB; Zhang FJ; Yu B; Bai YH; Wang YM; Ji YC; Zhou JQ; Liu XZ; Zhang ZY
Medicine (Baltimore); 2018 Dec; 97(50):e13675. PubMed ID: 30558073
[TBL] [Abstract][Full Text] [Related]
35. Increased intratumoral infiltration in IDH wild-type lower-grade gliomas observed with diffusion tensor imaging.
Aliotta E; Batchala PP; Schiff D; Lopes BM; Druzgal JT; Mukherjee S; Patel SH
J Neurooncol; 2019 Nov; 145(2):257-263. PubMed ID: 31531788
[TBL] [Abstract][Full Text] [Related]
36. Endothelin B receptor expression in malignant gliomas: the perivascular immune escape mechanism of gliomas.
Nakashima S; Sugita Y; Miyoshi H; Arakawa F; Muta H; Ishibashi Y; Niino D; Ohshima K; Terasaki M; Nakamura Y; Morioka M
J Neurooncol; 2016 Mar; 127(1):23-32. PubMed ID: 26645886
[TBL] [Abstract][Full Text] [Related]
37. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H
Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668
[TBL] [Abstract][Full Text] [Related]
38. Noninvasively evaluating the grade and IDH mutation status of gliomas by using mono-exponential, bi-exponential diffusion-weighted imaging and three-dimensional pseudo-continuous arterial spin labeling.
Guo D; Jiang B
Eur J Radiol; 2023 Mar; 160():110721. PubMed ID: 36738600
[TBL] [Abstract][Full Text] [Related]
39. Lower Lactate Levels and Lower Intracellular pH in Patients with
Wenger KJ; Steinbach JP; Bähr O; Pilatus U; Hattingen E
AJNR Am J Neuroradiol; 2020 Aug; 41(8):1414-1422. PubMed ID: 32646946
[TBL] [Abstract][Full Text] [Related]
40. Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas.
Yang P; Cai J; Yan W; Zhang W; Wang Y; Chen B; Li G; Li S; Wu C; Yao K; Li W; Peng X; You Y; Chen L; Jiang C; Qiu X; Jiang T;
Neuro Oncol; 2016 Aug; 18(8):1099-108. PubMed ID: 26957363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
